BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology
Xavier Ligneau(Inserm), Schwartz Jc, Walter Schunack, Christelle Anaclet, Jian‐Sheng Lin(Inserm), Isabelle Berrebi‐Bertrand, Florence Gbahou, Thierry Calmels, David Perrin, Laurent Landais, Régis Parmentier(Inserm), Valérie Bertaina‐Anglade, Holger Stark(Goethe University Frankfurt), JM Arrang, J.-C. Camelin, A. Rouleau, J.-M. Lecomte, C. Robin Ganellin, Christophe Drieu La Rochelle, F. d'Aniello
Cited by 234
Related Papers
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
|Pharmacological Reviews|2015|558
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
|Journal of Medicinal Chemistry|2018|476
Anatomical, Physiological, and Pharmacological Characteristics of Histidine Decarboxylase Knock-Out Mice: Evidence for the Role of Brain Histamine in Behavioral and Sleep–Wake Control
|Journal of Neuroscience|2002|470
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
|Nature Medicine|2003|381
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
|PLoS Computational Biology|2012|264